CY1123453T1 - Σκευασμα rna για ανοσοθεραπεια - Google Patents

Σκευασμα rna για ανοσοθεραπεια

Info

Publication number
CY1123453T1
CY1123453T1 CY20201100940T CY201100940T CY1123453T1 CY 1123453 T1 CY1123453 T1 CY 1123453T1 CY 20201100940 T CY20201100940 T CY 20201100940T CY 201100940 T CY201100940 T CY 201100940T CY 1123453 T1 CY1123453 T1 CY 1123453T1
Authority
CY
Cyprus
Prior art keywords
immunotherapy
rna preparation
rna
systemic administration
present
Prior art date
Application number
CY20201100940T
Other languages
English (en)
Inventor
Ugur Sahin
Heinrich Haas
Sebastian Kreiter
Mustafa DIKEN
Daniel Fritz
Martin MENG
Lena Mareen KRANZ
Kerstin REUTER
Original Assignee
Biontech Rna Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2012/001319 external-priority patent/WO2013143555A1/en
Application filed by Biontech Rna Pharmaceuticals Gmbh filed Critical Biontech Rna Pharmaceuticals Gmbh
Publication of CY1123453T1 publication Critical patent/CY1123453T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση συμπεριλαμβάνεται στο πεδίο της ανοσοθεραπείας, συγκεκριμένα της ανοσοθεραπείας όγκου. Η παρούσα εφεύρεση παρέχει φαρμακευτικά σκευάσματα για τη χορήγηση του RNA σε κύτταρα που παρουσιάζουν αντιγόνα όπως δενδριτικά κύτταρα (DC) στην σπλήνα μετά από συστημική χορήγηση. Πιο συγκεκριμένα, τα σκευάσματα που περιγράφονται εδώ επιτρέπουν την πρόκληση ανοσοαπόκρισης μετά από τη συστημική χορήγηση του RNA που κωδικοποιεί αντιγόνα.
CY20201100940T 2012-03-26 2020-10-07 Σκευασμα rna για ανοσοθεραπεια CY1123453T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2012/001319 WO2013143555A1 (en) 2012-03-26 2012-03-26 Rna formulation for immunotherapy
PCT/EP2013/000902 WO2013143683A1 (en) 2012-03-26 2013-03-25 Rna formulation for immunotherapy
EP13713356.7A EP2830593B1 (en) 2012-03-26 2013-03-25 Rna formulation for immunotherapy

Publications (1)

Publication Number Publication Date
CY1123453T1 true CY1123453T1 (el) 2022-03-24

Family

ID=52114006

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20191100389T CY1121697T1 (el) 2012-03-26 2019-04-09 Σκευασμα rna για ανοσοθεραπεια
CY20201100940T CY1123453T1 (el) 2012-03-26 2020-10-07 Σκευασμα rna για ανοσοθεραπεια

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20191100389T CY1121697T1 (el) 2012-03-26 2019-04-09 Σκευασμα rna για ανοσοθεραπεια

Country Status (8)

Country Link
EP (3) EP3777840A1 (el)
CY (2) CY1121697T1 (el)
DK (1) DK3427723T3 (el)
HR (1) HRP20190607T1 (el)
ME (1) ME03367B (el)
PL (2) PL2830593T3 (el)
RS (1) RS58794B1 (el)
SI (1) SI2830593T1 (el)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
SG11202002579SA (en) * 2017-10-20 2020-05-28 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
WO2020200472A1 (en) * 2019-04-05 2020-10-08 Biontech Rna Pharmaceuticals Gmbh Preparation and storage of liposomal rna formulations suitable for therapy
CN113225313A (zh) * 2021-03-26 2021-08-06 大唐三门峡发电有限责任公司 一种用于dcs系统的信息安全防护系统

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2010037408A1 (en) * 2008-09-30 2010-04-08 Curevac Gmbh Composition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
DE102008061522A1 (de) * 2008-12-10 2010-06-17 Biontech Ag Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung
WO2011005799A2 (en) * 2009-07-06 2011-01-13 Novartis Ag Self replicating rna molecules and uses thereof
BR112013000244A2 (pt) * 2010-07-06 2016-05-17 Novartis Ag lipossomas com lipídeos apresentando pka vantajoso para administração de rna
WO2013113325A1 (en) * 2012-01-31 2013-08-08 Curevac Gmbh Negatively charged nucleic acid comprising complexes for immunostimulation

Also Published As

Publication number Publication date
RS58794B1 (sr) 2019-07-31
EP2830593A1 (en) 2015-02-04
CY1121697T1 (el) 2020-07-31
DK3427723T3 (da) 2020-10-12
EP3427723A1 (en) 2019-01-16
EP2830593B1 (en) 2019-02-27
HRP20190607T1 (hr) 2019-07-12
PL2830593T3 (pl) 2019-08-30
EP3777840A1 (en) 2021-02-17
SI2830593T1 (sl) 2019-07-31
ME03367B (me) 2019-10-20
EP3427723B1 (en) 2020-08-05
PL3427723T3 (pl) 2021-01-11

Similar Documents

Publication Publication Date Title
TR201904758T4 (tr) İmmünoterapiye yönelik RNA formülasyonu.
CY1123453T1 (el) Σκευασμα rna για ανοσοθεραπεια
CY1121232T1 (el) Τριαλκυλο κατιονικα λιπιδια και μεθοδοι χρησης αυτων
MX2022003698A (es) Composiciones de nanoparticulas y metodos para inmunoterapia.
CY1120622T1 (el) Μεθοδοι και συνθεσεις για επαγωγη μιας ανοσιακης αποκρισης ως προς egfrviii
EA201290876A1 (ru) Композиции индуцированных дендритных клеток и их использование
MX2019004913A (es) Vacunas de nanoparticulas lipidicas que comprenden acido ribonucleico mensajero (arnm).
PH12015502638A1 (en) Novel immunotherapy against several tumors, such as lung cancer, including nsclc
BR112016009402A2 (pt) Peptídeo, linfócitos t citotóxicos (ltc) ativados, método para sua produção, anticorpo, receptor de células t, ácido nucleico, célula hospedeira, uso dos mesmos, kit, método para produzir uma vacina anticâncer personalizada para um paciente individual
CY1122453T1 (el) Νεα ανοσοθεραπεια εναντι διαφορων ογκων, οπως καρκινος του πνευμονα, οπου συμπεριλαμβανεται nsclc
CR20170419A (es) Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer.
EP4056198A3 (en) Outer membrane vesicles
MX363307B (es) Plataformas para suministro de antigenos.
EP3708185A3 (en) Novel immunotherapy against several tumors of the blood, in particular chronic lymphoid leukemia (cll)
MX2020011767A (es) Vacunas individualizadas para el cancer.
PE20142406A1 (es) Antigenos asociados a prostata y regimenes de inmunoterapia basados en vacuna
BR112013020070A8 (pt) moléculas de ácido nucleico que codificam novos antígenos de herpes, vacina compreendendo as mesmas e métodos de uso das mesmas
EA201490381A1 (ru) Синтетические наноносители, которые стимулируют формирование гуморального иммунного ответа и иммунного ответа, опосредованного цитотоксическими т-лимфоцитами (ctl)
MX349657B (es) Composiciones de vacuna de matriz de proteína que incluyen policationes.
MX2015017959A (es) Composiciones y metodos para inmunoterapia.
EA201590829A1 (ru) Новые мукозные адъюванты и системы доставки
MA37749A1 (fr) Vaccins contre les virus réassortis de la fièvre catarrhale et de la peste équine
CY1125328T1 (el) Ανασυνδυασμενο εμβολιο ιου λευχαιμιας αιλουροειδων περιεχοντας βελτιστοποιημενο γονιδιο φακελου ιου λευχαιμιας αιλουροειδων
MX364946B (es) Sistema adyuvante mejorado para la administración de vacunas orales.
MX2019007924A (es) Vacunas contra la influenza.